Scientists at the Baylor College of Medicine partnered with Biological E, an Indian pharmaceutical company, to engineer a new coronavirus vaccine. Based on clinical trials, the Corbevax vaccine shows 90% effectivity to the original variant and 80% effectivity to the Delta variant. The Corbevax vaccine is simple to manufacture and can be stored in standard refrigeration, making it easy to be mass distributed in low-income countries. These attributes are improvement upon the Pfizer and Moderna vaccines. The teams of scientists also developed the Corbevax vaccine without any patents, meaning the technology is freely available to any manufacturer. The hope is to make vaccinations available to even the poorest regions in the world. Less than half of the world's population is fully vaccinated against the virus. Already, there have been 150 million doses of Corbevax produced with another 100 million to be produced every month.